Osborne Clarke has advised iOnctura B.V. on the deal, iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has completed a €80 million Series...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here